Ardaman Shergill, MD, University of Chicago, Chicago, IL, provides an overview of influential trials presented at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in rectal and colorectal cancer, including findings from the CIRCULATE-US (NCT04089631), and the Phase III FOxTROT (NCT00647530) trials. Dr Shergill additionally highlights advances in the use of immunotherapy in microsatellite instability (MSI)-high colorectal cancer. This interview took place at the ASCO 2023 GI Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть